According to these findings, treatment with 160 mg valsartan/ 25 mg HCTZ totally dominates and it should be preferable. Sensitivity analysis confirmed the results from this base case.
aimed at training physicians to educate HBP patients. OBJECTIVES: Assessing the impact of CV@Goal on HBP patients and physicians. METHODS: A 6-month before-after comparison of physician and HBP patient populations. Four HBP patients per GPs were included. GPs were trained to educate HBP patients and included four new HBP patients. RESULTS: In total, 1208 HBP patients and 308 physicians completed the "before" questionnaire, and after training 512 new patients and 169 physicians completed the "after" questionnaire. According to GPs, there were in both phases "important" or "insurmountable difficulties" concerning patient sedentary lifestyle (40%), diet compliance (60%) and alcohol (75%). The proportion of GPs who considered patient knowledge to be "good" or "very good" increased for: general issues (22% to 38%), the disease natural history (8% to 14%), risks (29% to 49%), complication prevention (13% to 24.5%) and alarm symptoms (21% to 35%); the proportion also increased for patient awareness of the importance of smoking cessation (69% to 77%) and special dieting (52% to 67%). Changes in patients' blood pressure were not significant. Most patients believed smoking, diabetes, alcohol, hypercholesterolemia, treatment compliance, obesity, age, heredity and diet could alter blood pressure; knew HBP could relate to heart, brain, arteries, eyes, kidneys complications; that smoking cessation, weight loss, physical exercise and salt reduction could improve HBP. After CV@Goal, improvements were observed in patient knowledge about the importance of weight loss, physical exercise and salt consumption. Nevertheless, most patients declare they have not changed lifestyle since the HBP diagnosis. CONCLUSION: CV@Goal had an impact on patient knowledge about HBP, but not on lifestyle and BP. 3 Euroclin Institute, Madrid, Spain OBJECTIVES: Hypertensive patients with cardiovascular (CV) disease or diabetes are at a particularly high CV risk. LDLcholesterol (cLDL) levels are an important CV risk factor and total cholesterol/cHDL (TC/HDL) ratio is also related to cardiovascular risk. Although HDL-cholesterol (cHDL) is a protective factor, available therapeutic strategies are not effective enough. The objective of this study is to compare cLDL, cHDL and TC/HDL between two groups: patients with previous CV disease/diabetes and those without it in a hypertensive population from a programme for CV risk control. METHODS: A total of 5094 subjects from primary care centres in Spain were retrospectively studied. Levels of cLDL, cHDL and TC/HDL were compared for the above mentioned groups by Student t test for independent samples. RESULTS: There were 41.4% men. Mean age 66.3 years. Average TC levels were: 214.4 mg/dL; cLDL: 141.9 mg/dL; cHDL: 45.5 mg/dL and TC/HDL: 4.98. Levels of cLDL were significantly lower for those with CV disease/diabetes: 148.6 mg/dL (SD 32.8) vs. 132.3 mg/dL (SD 35); p < 0.0001. Similarly, Levels of cHDL were significantly lower for those with CV disease/diabetes: 47.1 mg/dL (SD 12.5) vs. 43.1 mg/dL (SD 11.4): p < 0.0001. There were no significant differences of CT/HDL ratio between groups. CONCLUSIONS: In a population of treated hypertensives, cLDL levels are lower for those with previous CV disease/diabetes, which is appropriate taking into account their higher cardiovascular risk. On the contrary cHDL levels are lower in the group at highest risk. There is a wide room for improvement of cardiovascular risk in hypertensive patients with previous CV disease or diabetes, by increasing HDL. For 2000 For -2004 , the data about consumption of drugs for cardiovascular disease were collected, in accordance with the Anatomic Therapeutic Chemical classification (ATC: C01-C10) and Defined Daily Dose (DDD) measurement unit. This analysis focused on the situation in antihypertensive medication in more detail. Data of wholesalers, who are legally obliged provide this information to the SUKL, was used for the analysis. RESULTS: A significant increase in the medication of cardiovascular disease (in 2000 (290.27), in 2002 (376.30) and in 2004 (388.06) 2 Novartis, México, DF, Mexico OBJETIVE: To estimate the cost-effectiveness of 160 mg valsartan as an alternative treatment for systemic arterial hypertension as compared with daily doses of 100 mg losartan and 80 mg telmisartan using a pharmaco-economic analysis. METHOD-OLOGY: The study was based on a literature review and expert opinion in two phases: the first was a literature search to determine effectiveness expressed as a reduction of mm Hg; the second consisted of a cost-effectiveness analysis. The model used the Mexican Health System perspective. Only direct medical costs were included. Data costs were obtained from published lists of unitary costs for the Health Sector. RESULTS: Following treatment with 160 mg valsartan and 100 mg losartan for 4 weeks, the mean sitting diastolic blood pressure (MSDBP) was -10.5 mm Hg and -9.7 mm Hg respectively. The difference was not significantly significant. In the case of valsartan versus 80 mg telmisartan, valsartan proved more effectiveness, showing a reduction in systolic and diastolic pressure of -18.6 and -12.1 mm Hg respectively as compared with reductions of -10.8 and -8.4 mm Hg for telmisartan. The cost analysis did not show any differences in terms of other medical interventions but there was a difference in the cost of the drugs. The monthly cost per patient treated was the lowest with 160 mg valsartan at $246.67 Mexican pesos (US$22.42), as compared with $695.60 Mexican pesos (US$63.23) for 100 mg losartan and $469.29 ($42.66) for 80 mg telmisartan. CONCLUSIONS: Treatment with 160 mg valsartan is the least costly with at least the same efficacy in reducing arterial pressure as 100 mg daily dose of losartan. In the case of 80 mg telmisartan, 160 mg valsartan was more effective with a lower cost. It has been shown that 160 mg valsartan is the preferred treatment in terms of pharmaco-economic parameters compared with the other options studied. Sensitivity analysis confirmed the results obtained in the base case. To investigate if there are differences in the persistence and compliance to therapy depending on the antihypertensive drug class prescribed first (index drug). METHODS: Prescription claims data were analysed for the 2000 to 2003 time period. Index prescriptions were determined for: ACE-inhibitors (ACEi), angiotensin receptor blockers (ARB), beta blockers (BETA), calcium channel blockers (CCB), and diuretics (DIU). Patients regarded as newly diagnosed (i.e., without any antihypertensive medication 180 days before the index time point) with a follow-up of at least 360 days were included in the study. Persistence rates (percentage of beneficiaries on continuous therapy with the index drug at 180 and 360 days) were calculated for each drug class. Compliance was determined in terms of the medication possession ratio (MPR) for 180 and 360 days (dispensed supply in defined daily dose (DDD) within 180 and 360 days
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PCV66 PATIENTS ON ARBS (AND VALSARTAN AS A REPRESENTATIVE) EXPERIENCE HIGHER PERSISTENCE AND COMPLIANCE (ADHERENCE) WITH THERAPY COMPARED TO OTHER ANTIHYPERTENSIVE CLASSES IN A GERMAN SICKNESS FUND POPULATION
